| Literature DB >> 28879225 |
Greger Olsson1,2, Farshad Frozanpor3, Lars Lundell1, Lars Enochsson1, Christoph Ansorge1, Marco Del Chiaro1, Marcus Reuterwall-Hansson1, Alysha Shetye1, Urban Arnelo1.
Abstract
BACKGROUND AND STUDY AIMS: Preoperative biliary drainage in patients with periampullary tumors and jaundice has been popularized to improve the quality of life and minimize the risks associated with subsequent radical surgery. The aim of this study was to investigate the possible superiority of self-expandable metal stents (SEMS) over plastic stents, by comparing the amount of bacteria in intraoperatively collected bile and using this variable as a proxy for the efficacy of the respective biliary drainage modalities. PATIENTS AND METHODS: In this randomized clinical trial, 92 patients with obstructive jaundice were enrolled; 45 were allocated to the plastic stent group and 47 to the SEMS group. The primary outcome was the extent and magnitude of biliary bacterial growth at the time of surgical exploration. Secondary outcomes were: macroscopic grading of inflammation of the stented bile ducts, occurrence of adverse events after stenting, stent dysfunction, recognized surgical complexities, and incidence of postoperative complications.Entities:
Year: 2017 PMID: 28879225 PMCID: PMC5585071 DOI: 10.1055/s-0043-110565
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Flow chart depicting the allocation of cases to respective study groups. SEMS, self-expandable metal stent.
Demographic and clinical characteristics of patients undergoing exploratory surgery.
| Plastic stent n = 34 | SEMS n = 34 |
| |
|
| |||
| BMI, median (range), kg/m 2 | 24.1 (19.4 – 38.9) | 23.8 (18.4 – 37.7) | 0.40 |
| Age, median (range), years | 68 (42 – 81) | 69 (51 – 81) | 0.82 |
| Sex, males, n (%) | 23 (67) | 17 (50) | 0.14 |
| Bilirubin, pre-ERCP, median (range), μmol/L | 181 (60 – 407) | 176 (68 – 398) | 0.70 |
| CRP, pre-ERCP, median (range), mg/L | 9 (1 – 103) | 20 (1 – 181) | 0.01 |
|
| |||
| Tumor size, median (range), mm | 25 (10 – 44) | 25 (5 – 60) | 0.89 |
| Length of stenosis, median (range), mm | 15 (5 – 70) | 20 (5 – 30) | 0.28 |
| Tumor stage (TNM), n (%) | n = 32 | n = 33 | |
Stage I | 3 (9) | 1 (3) | 0.61 |
Stage II | 19 (59) | 25 (76) | 0.13 |
Stage III | 7 (22) | 2 (6) | 0.15 |
Stage IV | 3 (9) | 5 (15) | 0.57 |
| Tumor differentiation, n (%) | |||
Well differentiated | 0 (0) | 1 (4) | 0.31 |
Moderately differentiated | 15 (50) | 10 (40) | 0.21 |
Poorly differentiated | 15 (50) | 14 (56) | 0.81 |
| Tumor type, n (%) | |||
Pancreatic | 27 (79) | 29 (85) | 0.52 |
Biliary | 2 (6) | 1 (3) | 0.55 |
Papillary | 4 (12) | 3 (9) | 0.69 |
No tumor cells found | 1 (3) | 0 (0) | > 0.99 |
Duodenal | 0 (0) | 1 (3) | > 0.99 |
| Pancreatic tissue type, n (%) | n = 25 | n = 22 | |
Soft | 5 (20) | 3 (14) | 0.70 |
Intermediate | 5 (20) | 4 (18) | > 0.99 |
Hard | 15 (60) | 15 (68) | 0.56 |
SEMS, self-expandable metal stent; BMI, body mass index; ERCP, endoscopic retrograde cholangiopancreatography; CRP, C-reactive protein; TNM, tumor, node, metastasis classification.
Results of bacterial cultures from intraoperatively collected bile.
| Bacterial cultures | |||
| Plastic stent (n = 27: 1 bypass + 26 resections) | SEMS (n = 24 resections) |
| |
| Bacteria count, median (IQR), CFU/mL | |||
| All bacteria species | 110 000 (100 000 – 200 000) | 131 000 (21050 – 21 0000) | 0.44 |
| Gut bacteria | 100 000 (2000 – 160 000) | 100 000 (11 600 – 160 000) | 0.58 |
|
| |||
| Plastic stent | CFU/mL | SEMS | CFU/mL |
|
| 1 450 000 |
| 642 000 |
|
Alpha
| 721 000 |
| 581 000 |
|
| 510 000 |
Alpha
| 389 000 |
| Enterobacteriacae spp. | 543 000 |
| 310 000 |
|
| 111 000 | Enterobacteriacae spp. | 211 000 |
|
| 101 000 |
| 205 000 |
|
| 100 000 |
| 130 000 |
| Leclercia spp. | 100 000 |
| 110 000 |
|
| 80 000 |
| 110 000 |
|
| 60 000 |
| 100 000 |
|
| 100 000 | ||
|
| 65 000 | ||
|
| 11 000 | ||
|
| 10 000 | ||
|
| 7000 | ||
|
| 5000 | ||
SEMS, self-expandable metal stent; IQR, interquartile range.
Preoperative adverse events and clinical characteristics at operation.
| Plastic stent | SEMS |
| |
|
| n = 45 | n = 47 | |
| Preoperative complications, n (%) | |||
Stent dysfunction | 12 (27) | 5 (11) | 0.05 |
Stent exchange | 11 (24) | 4 (9) | 0.05 |
Cholecystitis | 1 (2) | 4 (9) | 0.36 |
Cholangitis | 2 (4) | 1 (2) | 0.61 |
Pancreatitis | 3 (7) | 8 (17) | 0.20 |
|
| n = 34 | n = 34 | |
| Clinical characteristics at operation | |||
Bilirubin, median (range), μmol/L | 22 (2 – 363) | 18 (4 – 166) | 0.13 |
CRP, median (range), mg/L | 2 (1 – 130) | 6 (1 – 56) | 0.92 |
Cholangitis preoperative, n (%) | 6 (18) | 2 (6) | 0.26 |
Prophylactic antibiotics at ERCP, n (%) | 17 (50) | 18 (53) | 0.81 |
Previous sphincterotomy, n (%) | 3 (9) | 1 (3) | 0.61 |
Precut sphincterotomy, n (%) | 11 (32) | 11 (32) | > 0.99 |
Failed first cannulation at ERCP, n (%) | 4 (12) | 6 (18) | 0.73 |
| Preoperative complications, n (%) | |||
Stent dysfunction | 7 (21) | 2 (6) | 0.15 |
Pancreatitis | 2 (6) | 7 (21) | 0.15 |
Cholecystitis | 1 (3) | 3 (9) | 0.61 |
Cholangitis | 0 (0) | 1 (3) | > 0.99 |
Stent exchange | 6 (18) | 1 (3) | 0.11 |
|
| n = 32 | n = 27 | |
| Clinical characteristics at operation | |||
Bilirubin at operation, median (range), μmol/L | 21.5 (2 – 363) | 18 (4 – 166) | 0.16 |
CRP, median (range), mg/L | 2.5 (1 – 130) | 7.6 (1 – 47) | 0.62 |
Cholangitis preoperative, n (%) | 6 (19) | 2 (7) | 0.27 |
Prophylactic antibiotics at ERCP, n (%) | 15 (47) | 15 (56) | 0.51 |
Previous sphincterotomy, n (%) | 3 (9) | 0 (0) | 0.24 |
Precut sphincterotomy, n (%) | 11 (34) | 9 (33) | 0.93 |
Failed first cannulation at ERCP, n (%) | 4 (12) | 3 (11) | > 0.99 |
| Preoperative complications, n (%) | |||
Stent dysfunction | 7 (22) | 1 (4) | 0.06 |
Pancreatitis | 2 (6) | 3 (11) | 0.65 |
Cholecystitis | 1 (3) | 2 (7) | 0.59 |
Cholangitis | 0 (0) | 1 (4) | 0.46 |
Stent exchange, n (%) | 6 (19) | 0 (0) | 0.03 |
SEMS, self-expandable metal stent; CRP, C-reactive protein; ERCP, endoscopic retrograde cholangiopancreatography.
Includes curative and palliative surgery.
Intraoperative and histopathological findings in all patients undergoing surgery (curative and palliative).
| Plastic stent (n = 34) | SEMS (n = 34) |
| |
|
| |||
| Operation time, median (range), minutes | 398 (165 – 565) | 395 (134 – 627) | 0.66 |
| Intraoperative bleeding, median (range), mL | 880 (100 – 6800) | 800 (100 – 6700) | 0.90 |
| Vascular resection, n (%) | 8 (24) | 5 (15) | 0.38 |
| Total pancreatectomy, n (%) | 2 (6) | 3 (10) | 0.65 |
| Palliative double bypass, n (%) | 2 (6) | 2 (6) | > 0.99 |
| Explorative laparotomy only, n (%) | 0 (0) | 5 (15) | 0.05 |
|
| |||
| Subjective evaluation | 16 (47) | 17 (59) | 0.36 |
| No inflammation | 18 (53) | 12 (41) | 0.65 |
| Mild inflammation | 5 (15) | 6 (21) | 0.53 |
| Moderate inflammation | 6 (18) | 7 (24) | 0.53 |
| Severe Inflammation | 5 (15) | 4 (14) | > 0.99 |
| Difficulties creating hepaticojejunostomy | |||
None | 30 (88) | 29 (100) | 0.06 |
Some | 3 (9) | 0 (0) | 0.24 |
Severe | 1 (3) | 0 (0) | > 0.99 |
| Difficulties extracting stent | 0 (0) | 0 (0) | > 0.99 |
|
|
|
| |
| Histiocytosis | 9 (26) | 2 (7) | 0.05 |
None | 25 (74) | 27 (93) | 0.04 |
Mild | 5 (15) | 1 (3) | 0.20 |
Moderate | 4 (12) | 1 (3) | 0.36 |
| Cholangitis | n = 32 | n = 25 | |
None | 1 (3) | 0 (0) | > 0.99 |
Mild | 11 (34) | 8 (32) | 0.85 |
Moderate | 20 (62) | 16 (64) | 0.91 |
Severe | 0 (0) | 1 (4.0) | 0.44 |
SEMS, self-expandable metal stent.
Postoperative adverse events in all patients undergoing surgery (curative and palliative).
| Plastic stent (n = 34) | SEMS (n = 34) |
| |
| Perioperative outcomes | |||
Time from ERCP to surgery, median (range), days | 36 (16 – 278) | 31 (9 – 206) | 0.30 |
Time in hospital, median (range), days | 16 (4 – 46) | 14 (7 – 65) | 0.94 |
Time in HDU, mean (range), days | 3.4 (0 – 9) | 3.6 (0 – 10) | 0.84 |
| Postoperative complications, n (%) | |||
Overall | 23 (68) | 17 (50) | 0.14 |
Surgical | 17 (50) | 12 (35) | 0.22 |
Received antibiotics | 17 (50) | 20 (59) | 0.47 |
Anastomotic leakage | 4 (12) | 1 (3) | 0.36 |
Infection/abscess | 5 (15) | 10 (29) | 0.14 |
Postoperative bleeding | 3 (9) | 1 (3) | 0.61 |
Delayed gastric emptying | 8 (24) | 7 (21) | 0.77 |
Reoperation | 2 (6) | 1 (3) | > 0.99 |
Wound dehiscence | 1 (3) | 0 (0) | > 0.99 |
Cardiopulmonary | 6 (18) | 4 (12) | 0.73 |
| Complication severity, n (%) | |||
Clavien-Dindo I | 5 (15) | 3 (9) | 0.48 |
Clavien-Dindo II | 10 (29) | 6 (18) | 0.25 |
Clavien-Dindo III | 7 (21) | 7 (21) | > 0.99 |
Clavien-Dindo IV | 1 (3) | 0 (0) | > 0.99 |
SEMS, self-expandable metal stent; HDU, high dependency unit.
Postoperative adverse events in patients undergoing curative resection.
| Plastic stent (n = 32) | SEMS (n = 27) |
| |
| Perioperative outcomes | |||
Mortality, n (%) | 0 | 0 | > 0.99 |
Time in hospital, median (range), days | 16 (7 – 46) | 15 (10 – 65) | 0.84 |
Time in HDU, mean (range), days | 3.5 (0 – 9) | 4.0 (0 – 10) | 0.49 |
Operation time, median (range), minutes | 402 (229 – 565) | 420 (290 – 627) | 0.42 |
Intraoperative bleeding, median (range), mL | 1000 (150 – 6800) | 1050 (100 – 6700) | 0.87 |
Vascular resection, n (%) | 8 (25) | 5 (19) | 0.64 |
| Postoperative complications, n (%) | |||
Overall | 23 (72) | 14 (52) | 0.11 |
Surgical | 17 (53) | 12 (44) | 0.51 |
Received antibiotics | 17 (53) | 15 (56) | 0.85 |
Anastomotic leakage | 4 (12) | 1 (4) | 0.36 |
Infection/abscess | 5 (16) | 6 (22) | 0.51 |
Postoperative bleeding | 3 (9) | 1 (4) | 0.62 |
Delayed gastric emptying | 8 (25) | 7 (26) | 0.94 |
Reoperation | 2 (6) | 1 (4) | > 0.99 |
Wound dehiscence | 1 (3) | 0 (0) | > 0.99 |
Cardiopulmonary | 6 (19) | 4 (15) | 0.74 |
| Complication severity, n (%) | |||
Clavien-Dindo I | 5 (16) | 3 (11) | 0.72 |
Clavien-Dindo II | 10 (31) | 4 (15) | 0.22 |
Clavien-Dindo III | 7 (22) | 6 (22) | 0.97 |
Clavien-Dindo IV | 1 (3) | 0 (0) | > 0.99 |
SEMS, self-expandable metal stent; HDU, high dependency unit.